Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $32.98
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 30, 26 |
| RBC Capital |
| maintain |
| Outperform |
| Outperform |
| May 19, 26 | RBC Capital | maintain | Outperform | Outperform |
| May 7, 26 | RBC Capital | maintain | Outperform | Outperform |
| Mar 12, 26 | Goldman Sachs | maintain | Buy | Buy |
| Feb 20, 26 | RBC Capital | maintain | Outperform | Outperform |
| Feb 18, 26 | RBC Capital | maintain | Outperform | Outperform |
| Jan 20, 26 | JP Morgan | downgrade | Overweight | Neutral |
| Nov 17, 25 | RBC Capital | maintain | Outperform | Outperform |
| Aug 1, 25 | RBC Capital | maintain | Outperform | Outperform |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
FY2020 · 10-K disclosure
FY2020 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 5, 2026 | 2026-10-05 09:17:15 | View |
| SD | Sep 15, 2026 | 2026-09-15 11:12:55 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 17:08:10 | View |
| 6-K | Jul 29, 2026 | 2026-07-29 11:15:50 | View |
| SC 13G/A | May 14, 2026 | 2026-05-14 13:55:35 | View |
| 6-K | May 7, 2026 | 2026-05-06 18:43:10 | View |
| 6-K | May 6, 2026 | 2026-05-06 11:17:21 | View |
| 6-K | Apr 1, 2026 | 2026-04-01 17:18:32 | View |
| 6-K | Apr 1, 2026 | 2026-04-01 17:16:47 | View |
| 6-K | Apr 1, 2026 | 2026-04-01 17:14:36 | View |
Proxy statement (DEF 14A) disclosures
1255 daily bars · split adjusted
TTM vs. 5-year historical average (annual ratios)
| Metric | CVE | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 12.8x | 19.1x · sector 14.8x | In line |
| Forward P/E (FY26E) | 5.7x | EPS est. 5.75 | Discount |
| Price / Book | 2.5x | 1.5x | Elevated |
| Price / Sales | 1.6x | 0.7x | Elevated |
| EV / EBITDA | 6.3x | 5.2x | Elevated |
| Return on equity | 21.0% | — | Top tier |
| Gross margin | 21.4% | 19.6% | In line |
| Debt / Equity | 0.34 | 0.46 | Conservative |
| Piotroski / Altman Z | 6/9 | Z 3.33 | Safe zone |
Discounted cash flow model
Daily · Wilder smoothing
Stock news · updated daily
Cenovus (CVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 56.11 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 67.23 | Oscillator | Neutral |
| Williams %R (14) | -23.61 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.32 (Hist 0.09) | Oscillator | Strong Buy |
| Average Directional Index (14) | 12.81 (+DI 18.5 / -DI 20.1) | Trend | Neutral |
| EMA 20 | 32.30 | MA | Buy |
| SMA 20 | 32.01 | MA | Strong Buy |
| EMA 50 | 31.64 | MA | Strong Buy |
| SMA 50 | 32.18 | MA | Buy |
| SMA 200 | 27.12 | MA | Strong Buy |
EQNR and CVE benefit from strong energy markets and production growth, but a sharp valuation gap makes one stock a more compelling investment.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | 1.11 | 1.11 | Beat 0.0% | $14.59B |
| May 6, 2026 | 0.56 | 0.61 | Beat 8.9% | $8.47B |
| Feb 19, 2026 | 0.28 | 0.36 | Beat 28.6% | $9.42B |
| Oct 31, 2025 | 0.40 | 0.52 | Beat 30.0% | $9.46B |
| Jul 31, 2025 | 0.14 | 0.33 | Beat 135.7% | $9.04B |
| May 8, 2025 | 0.29 | 0.32 | Beat 10.3% | $9.97B |